MX9706062A - FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA. - Google Patents
FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.Info
- Publication number
- MX9706062A MX9706062A MX9706062A MX9706062A MX9706062A MX 9706062 A MX9706062 A MX 9706062A MX 9706062 A MX9706062 A MX 9706062A MX 9706062 A MX9706062 A MX 9706062A MX 9706062 A MX9706062 A MX 9706062A
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- lactam antibiotic
- oral dosage
- granulate
- forms containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Se proporciona un granulado que contiene 50-99,9% en peso de un antibiotico de beta-lactama soluble en agua, 0-50% en peso de un producto de la celulosa el cual es celulosa microcristalina, celulosa microfina o una mezcla de las mismas, y 0-0,5% en peso de un agente aglutinante para la granulacion en humedo. Se describe un proceso para la preparacion de un granulado que comprende un antibiotico de beta-lactama soluble en agua, cuyo proceso comprende humedecer los componentes del granulado con un líquido esencialmente acuoso sin emplear una cantidad importante de un agente aglutinante para la granulacion en humedo (0-0,5% en peso) y tamizar consecutivamente los granulados humedos y secos a través de un tamiz de por lo menos 0,71 mm. Los granulados se mezclan convenientemente con un producto de celulosa, el cual es celulosa microcristalina, celulosa microfina o una mezcla de las mismas, y uno o más desintegrantes para utilizarse en formas de dosificacion oral rápidamente dispersables, cuando se ponen en un ambiente acuoso. El sabor de dichas formas de dosificacion oral se mejora utilizando una combinacion de agentes edulcorantes y sazonantes. También se proporciona un proceso para la preparacion de dichas formas de dosificacion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95200313 | 1995-02-08 | ||
PCT/EP1996/000547 WO1996024337A1 (en) | 1995-02-08 | 1996-02-08 | ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9706062A true MX9706062A (es) | 1997-10-31 |
Family
ID=8220003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9706062A MX9706062A (es) | 1995-02-08 | 1996-02-08 | FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA. |
Country Status (19)
Country | Link |
---|---|
US (1) | US5948422A (es) |
EP (1) | EP0801559B1 (es) |
CN (1) | CN1125636C (es) |
AT (1) | ATE216576T1 (es) |
AU (1) | AU4789696A (es) |
BG (1) | BG63528B1 (es) |
BR (1) | BR9607189A (es) |
CZ (1) | CZ293718B6 (es) |
DE (1) | DE69620866T2 (es) |
DK (1) | DK0801559T3 (es) |
EA (2) | EA003736B1 (es) |
ES (1) | ES2175073T3 (es) |
HU (1) | HU227938B1 (es) |
MX (1) | MX9706062A (es) |
NO (1) | NO319993B1 (es) |
PL (1) | PL186386B1 (es) |
PT (1) | PT801559E (es) |
WO (1) | WO1996024337A1 (es) |
ZA (1) | ZA961018B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI225402B (en) | 1996-03-13 | 2004-12-21 | Biochemie Gmbh | Auxiliary-free agglomerates |
US6242006B1 (en) * | 1996-07-16 | 2001-06-05 | Gist-Brocades B.V. | β-lactam granules free of organic solvents |
US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
AU741992B2 (en) * | 1998-03-06 | 2001-12-13 | Adare Pharmaceuticals S.R.L. | Fast disintegrating tablets |
US7399751B2 (en) * | 1999-11-04 | 2008-07-15 | Sertoli Technologies, Inc. | Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells |
DE19922537A1 (de) * | 1999-05-10 | 2000-11-16 | Roland Bodmeier | Darreichungsform zur Applikation in Körperöffnungen |
US20040034039A1 (en) * | 2000-09-22 | 2004-02-19 | Yoshinori Nakano | Solid preparations |
GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
HUP0303178A3 (en) * | 2001-02-05 | 2008-03-28 | R P Scherer Technologies | Methods and compositions for reducing the taste of pharmaceutically active agents |
CN100337630C (zh) * | 2002-03-12 | 2007-09-19 | 布里斯托尔-迈尔斯斯奎布公司 | 可口的口服悬浮液及其制备方法 |
CA2500712C (en) * | 2002-10-02 | 2011-08-09 | Meiji Seika Kaisha, Ltd. | Antibiotic pharmaceutical composition with improved oral absorbability |
KR20050096922A (ko) * | 2002-12-20 | 2005-10-06 | 니코노범 에이비 | 물리적 및 화학적으로 안정된 니코틴 함유 입자물질 |
WO2005018540A2 (en) * | 2003-07-03 | 2005-03-03 | Jannette Dufour | Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
US20050089502A1 (en) * | 2003-08-21 | 2005-04-28 | Todd Schansberg | Effervescent delivery system |
WO2007061829A2 (en) | 2005-11-17 | 2007-05-31 | Novartis Ag | Pharmaceutical composition |
AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
CA2658951A1 (en) * | 2006-07-28 | 2008-01-31 | Sertocell Biotechnology (Us) Corp. | Adult sertoli cells and uses thereof |
WO2010031552A1 (en) * | 2008-09-17 | 2010-03-25 | Niconovum Ab | Process for preparing snuff composition |
US20120111756A1 (en) * | 2008-12-17 | 2012-05-10 | Altheus Therapeutics, Inc. | Enema formulations |
WO2023204773A1 (en) * | 2022-04-20 | 2023-10-26 | Bilim Ilac Sanayii Ve Ticaret A.S. | Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3344030A (en) * | 1964-06-15 | 1967-09-26 | American Home Prod | Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables |
DE2251250C3 (de) * | 1972-10-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten |
DE2251249A1 (de) * | 1972-10-19 | 1974-05-02 | Hoechst Ag | Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten |
DE3887179T2 (de) * | 1987-03-02 | 1994-06-16 | Brocades Pharma Bv | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. |
US5049394A (en) * | 1987-09-11 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Pharmaceutical composition containing high drug load and method for preparing same |
EP0330284B1 (en) * | 1988-02-25 | 1994-07-27 | Yamanouchi Europe B.V. | Process for the preparation of a pharmaceutical granulate |
US5643591A (en) * | 1991-01-16 | 1997-07-01 | Fmc Corporation | Solid dosage forms |
AU715177B2 (en) * | 1994-04-13 | 2000-01-20 | Research Corporation Technologies, Inc. | Methods of treating disease using sertoli cells and allografts or xenografts |
US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
-
1996
- 1996-02-08 BR BR9607189A patent/BR9607189A/pt active Search and Examination
- 1996-02-08 EA EA199900205A patent/EA003736B1/ru not_active IP Right Cessation
- 1996-02-08 HU HU9801677A patent/HU227938B1/hu not_active IP Right Cessation
- 1996-02-08 US US08/894,602 patent/US5948422A/en not_active Expired - Lifetime
- 1996-02-08 CN CN96191852A patent/CN1125636C/zh not_active Expired - Fee Related
- 1996-02-08 AT AT96904039T patent/ATE216576T1/de active
- 1996-02-08 WO PCT/EP1996/000547 patent/WO1996024337A1/en active IP Right Grant
- 1996-02-08 MX MX9706062A patent/MX9706062A/es unknown
- 1996-02-08 AU AU47896/96A patent/AU4789696A/en not_active Abandoned
- 1996-02-08 ES ES96904039T patent/ES2175073T3/es not_active Expired - Lifetime
- 1996-02-08 ZA ZA9601018A patent/ZA961018B/xx unknown
- 1996-02-08 CZ CZ19972302A patent/CZ293718B6/cs not_active IP Right Cessation
- 1996-02-08 EA EA199700093A patent/EA000361B1/ru not_active IP Right Cessation
- 1996-02-08 PT PT96904039T patent/PT801559E/pt unknown
- 1996-02-08 DK DK96904039T patent/DK0801559T3/da active
- 1996-02-08 DE DE69620866T patent/DE69620866T2/de not_active Expired - Lifetime
- 1996-02-08 PL PL96321567A patent/PL186386B1/pl unknown
- 1996-02-08 EP EP96904039A patent/EP0801559B1/en not_active Expired - Lifetime
-
1997
- 1997-08-07 NO NO19973646A patent/NO319993B1/no not_active IP Right Cessation
- 1997-08-08 BG BG101822A patent/BG63528B1/bg unknown
Also Published As
Publication number | Publication date |
---|---|
CN1173816A (zh) | 1998-02-18 |
EA003736B1 (ru) | 2003-08-28 |
DE69620866T2 (de) | 2003-02-27 |
ES2175073T3 (es) | 2002-11-16 |
EP0801559A1 (en) | 1997-10-22 |
PT801559E (pt) | 2002-09-30 |
AU4789696A (en) | 1996-08-27 |
NO973646L (no) | 1997-09-11 |
PL321567A1 (en) | 1997-12-08 |
ATE216576T1 (de) | 2002-05-15 |
BG63528B1 (bg) | 2002-04-30 |
ZA961018B (en) | 1997-08-08 |
DK0801559T3 (da) | 2002-06-17 |
BG101822A (en) | 1998-04-30 |
WO1996024337A1 (en) | 1996-08-15 |
HU227938B1 (en) | 2012-06-28 |
NO973646D0 (no) | 1997-08-07 |
PL186386B1 (pl) | 2004-01-30 |
DE69620866D1 (de) | 2002-05-29 |
HUP9801677A3 (en) | 1999-05-28 |
EA199900205A1 (ru) | 2000-06-26 |
EA199700093A1 (ru) | 1998-02-26 |
CN1125636C (zh) | 2003-10-29 |
EP0801559B1 (en) | 2002-04-24 |
CZ230297A3 (en) | 1997-11-12 |
US5948422A (en) | 1999-09-07 |
NO319993B1 (no) | 2005-10-10 |
HUP9801677A2 (hu) | 1998-11-30 |
BR9607189A (pt) | 1997-11-11 |
EA000361B1 (ru) | 1999-06-24 |
CZ293718B6 (cs) | 2004-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9706062A (es) | FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA. | |
HU206683B (en) | Process for producing 1,5-diphenyl-pyrazolo-3-carboxylic acid derivatives and selective herbicide compositions containing them as antidotum | |
BG103047A (en) | Granulate for the preparation of quick decomposition and quick dissolving compositions having high medicamentous form content | |
HUT43239A (en) | Plant protective compositions comprising acryl acid derivatives as active substance and process for preparing the active substances | |
UA42745C2 (uk) | Спосіб виготовлення таблеток, які містять пароксетин, та таблетка, яка містить пароксетин | |
HUT49366A (en) | Process for producing 2',3'-dideoxy-2',2'-difluoronucleosides and pharmaceutical compositions comprising same | |
HU9601358D0 (en) | Fluoro-phenyl-substituted alkenyl-carboxylic-guanidines, process for producing them, their use as medicines or diagnostica, and pharmaceutical compositions containing them | |
ATE288271T1 (de) | Stabile feste formulierung eines enalaprilsalzes und verfahren zu deren herstellung | |
HU9601321D0 (en) | Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them | |
IL83978A (en) | Process and compositions containing dihalopyridine derivatives for protecting plants against diseases,certain such novel derivatives and their preparation | |
HU905725D0 (en) | Process for producing 1,4-disubstituted 5-aryl-carbamoyl-4(6)-oxo-6(4)-oxido-pyrimidine-betaine derivatives and anthelmintic preparatives containing these compounds as active substance | |
ZA901543B (en) | Benzoxazolinone derivatives,process for preparing them and pharmaceutical compositions containing them | |
PL331588A1 (en) | Granulated products containing a water-soluble compound and cellulose | |
HUP9801439A3 (en) | Use of beta-d-galactopyranosyl-d-xyloses for the preparation of compositions and solutions intended to the evaluation of intestinal lactase, and production process of the said compds. | |
FR2787811B1 (fr) | Dextrose pulverulent et son procede de preparation | |
HU913540D0 (en) | Process for the protection of plant cultivation by using triazolyl- or imidazolyl-methyl-allyl-alcoholes, and the new compounds used in the process | |
EP0364601A4 (en) | Agent for imparting sustained-release properties to agricultural chemicals, sustained-release agricultural chemicals, and process for their preparation | |
EP0346908A3 (en) | Animal feed and procedure for granulating same | |
HUP0002767A3 (en) | Carbohydrate-based enzyme granulates | |
HU895896D0 (en) | Process for producing 1-amino-alkyl-3-oxy-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-one derivatives and pharmaceutical compositions containing them as active components | |
TW334424B (en) | L-arginine aldehyde derivatives process for preparing them and pharmaceutical composition | |
ZA828934B (en) | Tetrazole derivatives, process for preparing these compounds, and pharmaceutical compositions thereof | |
HU9303785D0 (en) | 2-thienyl-imidazo[2,1-b]benzothiazol-3-acetic acid derivatives, process for producing them and pharmaceutical compositions containing them | |
HUT57713A (en) | Process for producing azoxy derivatives and pharmaceutical compositions comprising same, as well as fungicidal compositions | |
HUT66204A (en) | Phytoactive compositions containing n-phosphonomethyl-clycine monoammonium salts as active ingredients and process for producing the compositions and the active ingredients |